Form 4: CRISPR Therapeutics Director Granted 13,000 Stock Options

CRISPR Therapeutics AG Director Harold Edward Fleming was granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

Summary

• Harold Edward Fleming, a Director of CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options.
• The stock options have an exercise price of $38.57 per share.
• The grant date for these options was June 5, 2025.
• The options will vest 100% in 12 equal monthly installments, commencing on June 30, 2025.
• The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the 2026 Annual General Meeting of Shareholders.
• The expiration date for these stock options is June 5, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued alignment between management and shareholder interests, and it is a routine compensation practice that reinforces long-term commitment.

Positives

• The grant of 13,000 stock options to Director Harold Edward Fleming aligns his interests with those of shareholders, incentivizing long-term performance and value creation.
• The structured vesting schedule over 12 months provides a clear incentive for continued engagement and contribution to the company's strategic objectives.

Future Outlook

The grant of stock options to a director indicates a long-term incentive structure designed to align management interests with shareholder value creation over the vesting and option exercise period, suggesting a focus on sustained performance.

Industry Context

The granting of stock options to directors is a common and established practice in the biotechnology and pharmaceutical industries, including gene-editing companies like CRISPR Therapeutics, serving as a key mechanism to attract, retain, and incentivize experienced personnel by aligning their financial interests with the company's long-term growth and shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, including those in the biotech sector, to incentivize long-term performance and align interests with shareholders.
• The specific exercise price of $38.57 and the number of options (13,000) would typically be benchmarked against peer companies' director compensation packages, considering factors such as company size, performance, and industry norms, although specific comparable data is not provided in this filing.

Related Party Transactions

• The grant of stock options to Director Harold Edward Fleming constitutes a related party transaction, which is a standard and disclosed form of compensation for board members.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, potentially leading to better long-term performance and strategic decisions.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Harold Edward Fleming will begin vesting 13,000 stock options in 12 equal monthly installments starting June 30, 2025.
• The options will become fully vested by the earlier of June 5, 2026, or the 2026 Annual General Meeting of Shareholders.
• Harold Edward Fleming may exercise these options at $38.57 per share at any time after vesting until the expiration date of June 5, 2035.

Key Dates

Recommendation

Keywords

CRISPR Therapeutics, CRSP, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Harold Edward Fleming